NEW ORLEANS – Percutaneous left atrial appendage (LAA) closure may be appropriate for people with atrial fibrillation (AFib), even if long-term anticoagulation is an option, according to the large CHAMPION-AF trial presented here.
Three years after LAA closure with the Watchman FLX device, statistical criteria for non-inferiority of the device to non-vitamin K antagonist oral anticoagulant (NOAC) therapy were met based on the composite of death from cardiovascular causes, stroke, or systemic embolism (5.7% vs 4.8%, HR 1.20, 95% CI 0.87–1.66). P<0.001 for non-inferiority).
Furthermore, there was a reduction in non-procedure-related bleeding with non-inferior efficacy of LAA occlusion (10.9% vs 19.0%, HR 0.55, 95% CI 0.45–0.67, P<0.001 for superiority), Sable Kar, MD, of Los Robles Medical Center in Thousand Oaks, California, reported at the annual meeting of the American College of Cardiology (ACC). CHAMPION-AF data was published simultaneously New England Journal of Medicine.
Kar concluded, “Watchman FLX left atrial appendage closure should be considered as an alternative to NOACs in the shared decision-making process with Afib patients who are considered suitable for long-term oral anticoagulation.”
At first glance, CHAMPION-AF offers some leeway to LAA occluders after closure-AF, a small randomized trial that failed to show that LAA closure (using different devices) was noninferior to NOAC therapy in a somewhat older, high-risk group.
However, it could be argued that the current trial relied on questionable statistical criteria to render the intervention non-inferiority: the case for Watchman FLX was helped by a lower than expected observed event rate (12% in each group) and a generous non-inferiority margin of 4.8 percentage points in CHAMPION-AF.
“It is hard to prove a negative. The biggest danger of false negatives is inadequate power, and the fact that the actual incidence of the primary endpoint event in each group was less than half the anticipated is difficult to ignore. This finding is an increasingly common observation, in that the modern risk of adverse outcomes of atrial fibrillation (fortunately for our patients) is significantly lower than in years past,” said Gregory Marcus, MD, of the University of California San Francisco. It is written in. editorial.
“Although the data in the current trial support expanding the idea of left atrial appendage closure to selected patients on a case-by-case basis, they are likely insufficient for a definitive declaration that this approach is as efficacious as conventional NOAC therapy in most patients with atrial fibrillation,” Marcus cautioned.
Additionally, although LAA occlusion is thromboembolic protective – given that the majority of thromboembolic complications attributed to Afib originate in the LAA – there was a trend toward more strokes in the LAA closure group in CHAMPION-AF (3.6% vs 2.5%, HR 1.46, 95% CI 0.94–2.27).
“The between-group difference in the incidence of ischemic stroke or systemic embolism seen in the CHAMPION-AF trial was 1 percentage point over 3 years, which corresponds to an increase of 0.3% per year among patients receiving the device,” Carr and colleagues reported. “The planned 5-year evaluation of the CHAMPION-AF trial will help determine whether the differences in rates of ischemic stroke or systemic embolism observed in this trial persist.”
“In any case, the story is evolving,” said ACC session discussant Jose Jogler, MD, of UT Southwestern Medical Center in Dallas. Patients are coming in at lower risk, he said, and the need for anticoagulation is reduced after successful resection. Additionally, the Watchman procedure is also becoming safer, and there is work underway to limit the need for anticoagulation and antiplatelets after the procedure.
Class IIa is currently recommended in percutaneous LAA closure. US guidelines For Afib patients at high risk of stroke who have contraindications to long-term anticoagulation. Depending on patient preference alone, LAA occlusion may be a reasonable alternative to anticoagulation, which has a weak IIB support.
“We should already be making shared decisions with our patients about these devices,” Pamela Mason, MD, of UVA Health in Charlottesville, Virginia, commented at the ACC press conference. Citing this, he said, “It is important to note that there are other trials that we are waiting for.” catalyst Investigation on another commercially available LAA occluder, Amulet.
study details
For the CHAMPION-AF trial, Kar’s group looked for Afib patients who had an increased risk of stroke (CHA).2ds2-VASC score ≥2 for men and ≥3 for women) and 3,000 randomized to LAA occlusion or NOAC therapy alone.
The average age of the group was 71.7 and 31.9% were women. cha2ds2-VASc score averaged 3.5 points and HAS-BLED score averaged 1.3 points. Less than half of the participants had previously undergone an Afib ablation procedure.
The LAA occlusion group received a successful Watchman FLX implantation in 98.8% of cases. After device implantation, patients received NOAC plus aspirin, NOAC monotherapy, or dual antiplatelet therapy for 3 months, after which aspirin or P2Y12 inhibitor monotherapy was recommended.
The incidence of device-related thrombus, which was defined as any tissue density at the face of the implant on CT or transesophageal echocardiography per 4 months, reached 4.8%. Ultimately, 1.8% 0F of the Watchman FLX group had a clinically relevant device-related thrombus that resulted in resumption of oral anticoagulation, and two of these individuals with device-related thrombus had a stroke.
Meanwhile, effective closure, defined as residual leakage of more than 3 mm, was seen in 98.6% of patients at 4 months.
Kar cautioned that the study results may not apply to all LAA closure devices. Generalizability may be limited to Afib patients overall, as the trial excluded those with advanced heart failure and reduced ejection fraction.
Additionally, details of which NOACs were used in CHAMPION-AF were not reported. Marcus pointed to apixaban (Eliquis) as a NOAC with a particularly good track record of reduced bleeding risk.
